FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
FDA is piloting one-day inspectional assessments for cosmetics facilities, increasing oversight under MoCRA. Businesses should prepare for unannounced inspections focusing on compliance with registration, listing, GMP, and safety records.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All cosmetics manufacturers, contract manufacturers, private-label makers, importers, and distributors subject to MoCRA. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; inspections can occur at any time.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA introduces one-day inspectional assessments to enhance oversight efficiency, potentially leading to more frequent and targeted inspections.
Who it affects
All cosmetics manufacturers, contract manufacturers, private-label makers, importers, and distributors subject to MoCRA.
What you must do
Ensure facility registration, product listings, safety substantiation, adverse event records, GMP compliance, and labeling are up to date and readily accessible.
Deadline
Immediately; inspections can occur at any time.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
- FDA Warns Retailers Selling Illegal Tobacco Products That Look Like Everyday Products